Copyright © 2016
Aridis Pharmaceuticals, Inc.
5941 Optical Court, San Jose, CA 95138
Current treatments require potent antibiotic regimens, however, natural occurring A. baumannii harbor multidrug resistant genes that can increasingly circumvent these regimens. Resistance mechanisms include reduced expression of drug importing porins, increased expression of various efflux pumps and drug degrading enzymes. As a result, there are reports that more than 36 % of clinical isolates are resistant to carbapenems. Moreover, multidrug resistant A. baumannii isolates have been reported that are resistant to all antibiotics used in the clinic, leaving no adequate treatment today.
Aridis is evaluating the development of therapeutic antibodies against A. baumannii. Previously, a phase II clinical study has shown that a therapeutic antibody can be an effective adjunctive therapy against pneumonia caused by Pseudomonas aeruginosa, a closely related species to A. baumannii. It reduced mortality and decreased length of stay in the ICU. Together with highly qualified academic collaborators, the research team at Aridis has started an antibody target identification program using a proteomic approach. The result is the identification of eight novel putative targets that are expressed during infection in humans and all are highly conserved among all sequenced A. baumannii genomes. An animal pneumonia model for A. baumannii infections showed proof of concept for passive and/or active immunization for most of these targets. Using functional screening assays, Aridis is currently selecting fully human monoclonal antibodies as lead candidates for the treatment of A. baumannii infections.
Acinetobacter Baumannii Bacteria
Breakthrough Therapies for
Antibiotic Resistant Infections